Lineage Cell Therapeutics(US:LCTX) Yahoo Finance·2026-03-31 07:19Company Overview - Lineage Cell Therapeutics Inc. (NYSE:LCTX) is recognized as one of the top penny stocks with potential for significant returns [1] - The company is focused on developing cell replacement therapies for critical illnesses, with a diverse portfolio of products at various stages of clinical development [4] Recent Developments - On March 24, Lineage announced the launch of COR1, a preclinical cell therapy program targeting corneal endothelial disease, utilizing its proprietary AlloSCOPE platform [2] - The management views the COR1 program as a natural extension of its platform, aimed at addressing the global shortage of donor corneal cells and expanding its presence in ophthalmology [2] - CEO Brian Culley highlighted the advancements in the AlloSCOPE "5D" manufacturing process, which could help reduce production costs through large-scale production [2] Financial Performance - For the fourth quarter, Lineage reported revenue of $6.6 million, a significant increase from $2.9 million in the previous year [3] - CEO Culley described 2025 as a productive year for the company, emphasizing its mission to pioneer allogeneic cell therapy outside oncology [3]